Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study

Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study

Background: Delgocitinib ointment, a topical Janus kinase inhibitor, is used as treatment of patients with atopic dermatitis (AD) aged ≥2 years in Japan. Although initiating appropriate and early treatment upon the onset of AD in childhood is important, the safety and efficacy of delgocitinib ointme...

Full description

Bibliographic Details
Main Authors: Hidemi Nakagawa, Atsuyuki Igarashi, Hidehisa Saeki, Kenji Kabashima, Tomomi Tamaki, Hironobu Kaino, Yasushi Miwa
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Allergology International
Subjects:
Administration, topical
Delgocitinib
Dermatitis, atopic
Janus kinase inhibitors
Safety
Online Access:http://www.sciencedirect.com/science/article/pii/S1323893023000412

Internet

http://www.sciencedirect.com/science/article/pii/S1323893023000412

Similar Items